Physiomics uses Virtual Tumour and other industry standard technologies to predict the effects of cancer treatment regimes for the biopharma industry.

How can we help you?

Solve cancer drug development challenges

Optimise combination regimens, manage drug resistance, scale up from mouse to human, predict immune-oncology effects

Learn more

See our range of cancer modelling experience

Find out more about drug targets, drug types and cell lines where we have significant experience

Learn more

Learn about Virtual Tumour

Flexible in-silico cell-cycle based model combining PK and PD effects to predict cancer growth inhibition.

Learn more

Any other questions?

If you don’t see what you need here, please contact us by clicking on the link below.

Contact Us

News & publications

Results of AGM

The Company held its Annual General Meeting at its offices in Oxford on 20th November 2018 and is pleased to announce that all resolutions put to…

Physiomics to host stand at EORTC Dublin

Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for…

Dispatch of Annual Report and Shareholder Circular

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report…

Dr Jim Millen interviewed by Proactive Investors

Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction. Please click here to…